Edwyn
Over the reviewed period (2021–2024), Johnson & Johnson’s reported revenue and gross profit figures reveal noticeable volatility. Excluding the placeholder values from 2020, 2021 shows robust performance with revenue of approximately 82.6 billion USD and gross profit near 54.2 billion USD. However, 2022’s figures—revenue at roughly 20.0 billion USD and gross profit at 13.8 billion USD—drop by more than 75%, marking a significant year-over-year contraction. The data then reflects a strong recovery in 2023, with revenue climbing to 85.2 billion USD and gross profit reaching 58.6 billion USD, and 2024 shows a further increase in revenue to about 88.8 billion USD and gross profit to 61.4 billion USD. Notably absent in all years is operating income, making it challenging to evaluate the company’s operational efficiency directly from these figures. Net income trends over the same period underscore substantial swings that merit close examination. In 2021, net income was recorded at 14.7 billion USD, but it dropped sharply to 4.5 billion USD in 2022—a decline of roughly 70%—before surging dramatically to 35.2 billion USD in 2023, an increase of over 650% year-over-year. In 2024, net income fell again to approximately 14.1 billion USD. These fluctuations, while derived solely from the available summarized data, indicate potential impacts from non-recurring items, shifts in tax or regulatory environments, or other operational adjustments common in the healthcare industry. Overall, despite the revenue recovery from 2022’s contraction and the resilience suggested by recent revenue growth, the volatility in net income calls for further scrutiny to assess the sustainability of earnings and the underlying cost structure.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.